Label Image (Lbl500907717)
This is a product label for "teleriraceran 560 MG" with 120 tablets. The label also indicates to store at room temperature.*
Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7717
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7717). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Levetiracetam-fig1 (Levetiracetam Fig1)
This text provides a graph showing the Responder Rate in Study 1, with a 250% reduction from baseline. The data points on the graph range from 5% to 39.6%. The text indicates that the data points marked with an asterisk (*) are statistically significant versus placebo.*
Levetiracetam-fig2 (Levetiracetam Fig2)
This text provides data from a study comparing the responder rates (250% reduction from baseline) in Study 2 during Period A for patients taking a placebo, 1000 mg/day of Levetiracetam, and 2000 mg/day of Levetiracetam. Among the findings, it is noted that the responder rate was statistically significant for the group taking 2000 mg/day of Levetiracetam compared to the placebo group.*
Levetiracetam-fig3 (Levetiracetam Fig3)
This text describes the Responder Rate in Study 3 with the percentage of participants achieving a >50% reduction from baseline. The results show that 45% of participants on Levetiracetam 3000 mg/day achieved this reduction compared to 39.4% on placebo. The text also indicates the statistical significance of the difference between the two groups.*
Levetiracetam-fig4 (Levetiracetam Fig4)
This is a chart showing the Responder Rate (50% Reduction from Baseline) in Study 4. The data compares the percentage of responders in the placebo group (N=97) and the levetiracetam group (N=101), indicating a statistically significant difference with the medication group having a higher rate.*
Levetiracetam-fig5 (Levetiracetam Fig5)
The Figure 5 depicts the Responder Rate for all patients aged 1 month to less than 4 years showing a greater than 50% reduction from baseline in Study 5. The data shows that Lovetracatam is statistically significant compared to the placebo group.*
Levetiracetam-fig6 (Levetiracetam Fig6)
This is a graph showing the responder rate (250% reduction from baseline) in primary generalized tonic-clonic (PGTC) seizure frequency per week in Study 7 for patients taking Placebo (N=84) and Levetiracetam (N=79). The graph indicates that 72.2% of patients in the Levetiracetam group had a positive response compared to 45.2% in the Placebo group. The difference was statistically significant, showing the effectiveness of Levetiracetam in reducing seizure frequency in PGTC patients.*
Levetiracetam-str (Levetiracetam Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
